The acquisition aims to enhance HYTN’s manufacturing processes, and specifically to increasing the yield of tryptamine in psychedelic mushrooms, and grants HYTN exclusive access to Prism’s ...
VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) "HYTN" or "The Company", a leader in the development, formulation, and manufacturing of ...
The Licensed IP, which represents Prism’s material asset, is currently undergoing patent review, and is actively being deployed in connection with the cultivation of psilocybin-containing mushrooms at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results